Menu
Not yet recruiting NCT06934590

Evaluate Safety and Tolerability of RX001 in Patients With KRAS Mutant Advanced NSCLC

Phase I Interventional Non-Small Cell Lung Cancer

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: RX001.
Who it may be relevant to
Registry conditions: Non-Small Cell Lung Cancer. Basic parameters: from 19 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
South Korea
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

An Open-label, Dose Escalation, Phase I Study to Evaluate Safety and Tolerability of RX001 in Patients With KRAS Mutant Advanced Non-small Cell Lung Cancer

Overview

This is an open-label, dose-escalation Phase I study to evaluate the safety and tolerability of RX001 monotherapy in patients with advanced KRAS mutant NSCLC. Subjects aged ≥19 years with advanced NSCLC with KRAS mutations will be enrolled. Based on the investigator's judgment of the lung tumor location, RX001 will be administered as a single intratumoral treatment via bronchoscopy or CT-guided percutaneous injection. Additionally, after conducting safety, tolerability, and preliminary anti-tumor efficacy assessments for all subjects up to Week 12 (D84) following IP administration, the collected data will be reviewed by the SRC for a comprehensive evaluation. If the IP is designated for long-term follow-up studies, monitoring for malignant tumor formation and other SAEs specified by the Ministry of Food and Drug Safety (MFDS) will be conducted for a minimum of 5 years.

Interventions

  • Drug RX001
    Subjects will receive a single RX001 (AAV-hRUNX3) treatment via Intra-tumoral injection

Primary outcome measures

  • Incidence of treatment-related serious adverse event (SAE) rate [Time frame: Observation for 12 weeks following a single dose]
Secondary outcome measures (3)
  • Objective response rate (ORR) [Time frame: Observation for 12 weeks following a single dose]
  • Progression-free survival (PFS) [Time frame: Observation for 12 weeks following a single dose]
  • Target Tumor Size [Time frame: Observation for 12 weeks following a single dose]

Eligibility criteria

Inclusion criteria

  • Adults aged ≥19 years, male or female
  • Subject with histologically and/or cytologically confirmed, unresectable advanced NSCLC for radical cure that are confirmed as PD for the standard of care currently known to have clinical benefits, or for which no currently available standard of care exists due to intolerance, ineligibility, treatment refusal, etc.
  • Subjects must have at least one evaluable and injectable lesion as assessed on CT images based on RECIST version 1.1.
  • Subjects with valid biopsy results documented the presence of KRAS mutation.
  • Subjects with an ECOG performance status of 0 or 1 and an expected survival of at least 12 weeks at the time of study participation.
  • Subjects with adequate hematologic and terminal organ function.
  • Subjects must voluntarily sign an informed consent form approved by the IRB. Subjects must have the willingness and ability to comply with all procedures required by the protocol.

Exclusion criteria

  • Subjects must not meet any of the following conditions:
  • Subjects with a history of or current comorbidities including:
  • Hematologic malignancies, such as lymphoma, or any other malignant tumors apart from the indication of this study.
  • Subjects with the cardiovascular conditions such as unstable angina and/or myocardial infarction within 1 year prior to screening
  • Subjects with the pulmonary baseline conditions:
  • Blood coagulation disorder
  • Active bleeding disorders (including gastrointestinal bleeding)
  • Subjects who have received antithrombotics, including antiplatelets or anticoagulants
  • Subjects who have received anticancer therapies within 28 days prior to trial participation, or who have not recovered or stabilized from all AEs caused by such treatments to baseline levels
  • Subjects who have received radical radiotherapy within 6 weeks prior to trial participation etc.
  • Subjects who have received live vaccines or attenuated vaccines within 4 weeks prior to study participation
  • Subjects with active HBV or HCV, or HIV positive
  • Subjects with severe infections requiring antibiotics, antifungal agents, or antiviral agents, or those with uncontrolled active infectious diseases
  • Subjects with any form of primary immunodeficiency or active autoimmune diseases
  • Subjects who have previously received intratumoral therapy for the target lesion
  • Ineligibility or inability to participate in the study at the investigator's discretion

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Treatment

Study locations

South Korea · 1 center
  • Konkuk University Medical Center — Seoul

Identifiers

NCT: NCT06934590 · GC-LCP1001

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗